Kendler K S, Bracha H S, Davis K L
Eur J Pharmacol. 1982 Apr 23;79(3-4):217-23. doi: 10.1016/0014-2999(82)90627-6.
Neuroleptic drugs have been shown to block brain dopamine (DA) receptors. The relative potency of neuroleptics at blocking DA postsynaptic receptors (PSRs) and autoreceptors (ARs) is less clear. To examine this question, the potency of 5 neuroleptics at inhibiting receptors (PSRs) and autoreceptors (ABs) is less clear. To examine this question, the potency of 5 neuroleptics at inhibiting the augmentation of mouse climbing behavior induced by a high dose of apomorphine (2.5 mg/kg) (presumably mediated by DA PSRs) was compared with their potency at inhibiting the suppression of climbing behavior induced by a low dose of apomorphine (0.45 mg/kg) (presumably mediated by DA Ars). Haloperidol and molindone had no AR-blocking ability even at doses that substantially blocked DA PSRs. Metoclopramide and fluphenazine had AR-blocking ability only at doses that produced substantial PSR blockade. Sulpiride blocked DA ARs at doses that had relatively litter PSR effect. It is concluded that neuroleptic drugs differ substantially in their relative potency at blocking DA ARs and PSRs.
抗精神病药物已被证明可阻断脑内多巴胺(DA)受体。抗精神病药物阻断DA突触后受体(PSR)和自身受体(AR)的相对效力尚不清楚。为了研究这个问题,比较了5种抗精神病药物抑制高剂量阿扑吗啡(2.5毫克/千克)诱导的小鼠攀爬行为增强(可能由DA PSR介导)的效力与其抑制低剂量阿扑吗啡(0.45毫克/千克)诱导的攀爬行为抑制(可能由DA AR介导)的效力。氟哌啶醇和吗茚酮即使在能显著阻断DA PSR的剂量下也没有AR阻断能力。胃复安和氟奋乃静仅在产生显著PSR阻断的剂量下才有AR阻断能力。舒必利在对PSR作用相对较小的剂量下就能阻断DA AR。结论是,抗精神病药物在阻断DA AR和PSR的相对效力上有很大差异。